Table 1.
Construction method of animal tumor model induced by chemical drugs.
| Chemical | Species | Injection | Dose | Type of tumor | Incidence | Reference |
|---|---|---|---|---|---|---|
| Urethan | A mice | i.p. | 1,000 mg/kg, single injection | Lung tumor | 6 months: 75% | (29) |
| BALB/c mice | i.p. | 600 mg/kg, three times every 2 days | Lung tumor | 20 weeks: 70% | (30) | |
| Swiss mice (newborn) | Breast-feeding | Parental female mice were administered 30 mg in 1, 3, and 5 days after delivery | Lung tumor | 3 months: 52%; 7 months: 78% | (31) | |
| Swiss mice (newborn) | i.h. | 2 mg, single injection | Lung tumor | 3 months: 100% | (31) | |
| C57BL/6J mice | i.p. | 1,000 mg/kg, once a week for 10 weeks | Lung tumor | 30 weeks: 100% | (32) | |
| NNK | A/J mice | i.p. | 100 mg/kg, single injection | Lung adenomas | 34–42 weeks: 50% | (33) |
| A/J mice | i.p. | 3 μmol weekly for 8 weeks | Lung adenomas | 26 weeks: 100% | (34) | |
| Swiss mice (newborn) | i.p. | 50 mg/kg, on postnatal days 1, 4, 7, 10, and 14 | Lung tumor | 13–15 months: 57% (male), 37% (female) | (35) | |
| DEN | FVB/N mice (15-day-old) | i.p. | 15 μg/g, single injection | Lung cancer (papillary cancer) | 12 months: 72% | (36) |
| C57BL/6 mice (male) | i.g. | 0.014% DEN for 6 days a week | Hepatocellular carcinoma | 11–15 weeks: 100% | (37) | |
| DEN+ CCl4 | B6C3F1/J mice(male) | i.p. (CCl4) i.v. (DEN) |
1 mg/kg DEN, 40.2 ml/kg CCL4 every week from week 8 to 14 | Liver adenoma/liver cancer | 22 weeks: 100% (liver adenoma), 50% (liver cancer) | (38) |
| ENU | SD rats (offspring) | i.v. (pregnant rats) | 50 mg/kg, on day 20 of their pregnancy | Nervous system tumor | 1 year: 100% | (39) |
| NTCU | SWR/J mice | Skin smear | 25-μl drop of 0.04 M, twice a week for 8 months | Lung squamous cell carcinoma | 8 months: 100% | (40) |
| NIH Swiss mice | Skin smear | 25-μl drop of 0.04 M, twice a week for 8 months | Lung squamous cell carcinoma | 8 months: 83% | (40) | |
| A/J mice | Skin smear | 25-μl drop of 0.04 M, twice a week for 8 months | Lung squamous cell carcinoma | 8 months: 75% | (40) | |
| FVB/J mice | Skin smear | 25-μl drop of 0.04 M, twice a week for 8 months | Lung squamous cell carcinoma | 8 months: 44% | (40) | |
| BALB/cJ mice | Skin smear | 25-μl drop of 0.04 M, twice a week for 8 months | Lung squamous cell carcinoma | 8 months: 38% | (40) | |
| DMBA | SD rats | i.g. | 80 mg/kg, gavaged once | Breast cancer | 12 weeks: 100% | (41) |
| NMBA | SD rats | i.h. | 0.5 mg/kg, three times a week for 5 weeks or once a week for 15 weeks | Esophageal tumors | 20 weeks: 100% | (42) |
| MCA | BC3Fl mice | Tracheal drip | 0.5 mg, 6 times a week | Respiratory tract squamous cell carcinoma | 10–28 weeks: 86% | (43) |
| DBA/2 mice | Tracheal drip | 0.5 mg, 6 times a week | Respiratory tract squamous cell carcinoma | 7 months: 6% | (43) | |
| AOM | A/J or FVB/N mice | i.p. | 10 mg/kg, once a week for 6 weeks | Colon tumors | 30 weeks: 80%–100% | (44) |